Tony Sehr

Dresden, SN 01307, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Gait dysfunction as an early marker of phenoconversion in REM sleep behavior disorder.

Gait dysfunction as an early marker of phenoconversion in REM sleep behavior disorder.

Journal: Scientific reports

Published: July 03, 2025

State-of-the-art sleep arousal detection evaluated on a comprehensive clinical dataset.

State-of-the-art sleep arousal detection evaluated on a comprehensive clinical dataset.

Journal: Scientific reports

Published: March 08, 2024

Effects of obstructive sleep apnea treatment on neurodegenerative biomarker neurofilament light chain and cognitive performance.

Effects of obstructive sleep apnea treatment on neurodegenerative biomarker neurofilament light chain and cognitive performance.

Journal: Journal of sleep research

Published: November 02, 2023

New Therapeutic Approaches for Chronic Insomnia

New Therapeutic Approaches for Chronic Insomnia

Journal: Fortschritte der Neurologie-Psychiatrie

Published: October 17, 2023

A pragmatic methodical framework for the user-centred development of an electronic process support for the sleep laboratory patients' management.

A pragmatic methodical framework for the user-centred development of an electronic process support for the sleep laboratory patients' management.

Journal: Digital health

Published: July 21, 2022

Fingolimod Leads to Immediate Immunological Changes Within 6 h After First Administration.

Fingolimod Leads to Immediate Immunological Changes Within 6 h After First Administration.

Journal: Frontiers in neurology

Published: January 27, 2020

Letter to the editor regarding "Therapeutic drug monitoring of natalizumab".

Letter to the editor regarding "Therapeutic drug monitoring of natalizumab".

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: April 04, 2019

Early central vs. peripheral immunological and neurobiological effects of fingolimod-a longitudinal study.

Early central vs. peripheral immunological and neurobiological effects of fingolimod-a longitudinal study.

Journal: Journal of molecular medicine (Berlin, Germany)

Published: February 15, 2019

Letter to the editor on the paper: "The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing".

Letter to the editor on the paper: "The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing".

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: August 15, 2017

Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS.

Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS.

Journal: Journal of neuroinflammation

Published: June 02, 2017

Fingolimod additionally acts as immunomodulator focused on the innate immune system beyond its prominent effects on lymphocyte recirculation.

Fingolimod additionally acts as immunomodulator focused on the innate immune system beyond its prominent effects on lymphocyte recirculation.

Journal: Journal of neuroinflammation

Published: December 15, 2016

New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies.

New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies.

Journal: Journal of neuroinflammation

Published: January 06, 2016

Showing 1-12 of 12

Last Updated: 09/26/2026